Barcelona, Spain – 21st September 2017 – Phagenesis announced today the official launch of the Phagenyx® Next Generation catheter, the result of company’s engagement to continuous innovation and product improvement.
The participants at 7th ESSD Congress and World Dysphagia Summit, Barcelona, 18-23 September 2017 will have the chance to see and test the new product at Phagenesis stand. The Phagenyx® Next Generation catheter allows an optimal and customised treatment, as well as safe feeding for every patient.
Phagenyx® is an evidence based innovative treatment targeting the cause of neurogenic dysphagia. It uses Pharyngeal Electrical Stimulation (PES) to restore neurological control of swallowing, thus reducing the risk of complications and associated costs and improving patient’s outcomes.
The Phagenyx® system delivers a calibrated electrical signal to the back of the throat (oropharynx) for 10 minutes a day for three consecutive days. Randomised controlled trials have shown that this protocol leads to a clinically and statistically significant improvement in swallowing function in the majority of patients with neurogenic dysphagia.
The treatment is based on over 20 years of research and development led by Professor Shaheen Hamdy at the University of Manchester, UK.